


## Put on your thinking caps....

- Does Google answer all my medical queries?
- Is it okay if I take medicines prescribed for my friend or family member if the symptoms seem the same?
- Can I swallow medications with a sip of any drink?
- Can I stop my antibiotics treatment or any other treatment midway, because I started to feel better?
- Spicy food and stress- are they the only culprits for ulcer?
- Do only overweight or obese people get diabetes?
- Do probiotics help prevent cold?
- Does taking multivitamins make me healthier?
- Should I take over-the-counter medications without consulting my doctor?

The answer to all these questions is - NO


BEWARE OF MYTHS AND STAY VIGILANT




















The old lady was feeling a bit off because of medication errors






















### What is an Adverse Event?

An adverse event or "AE" is any untoward medical occurrence in a patient after administration of a medicinal product, which may or may not have been caused by that medicine.

## **Reporting Criteria and Patient safety**

What special situations occurring in association with a medical product should trigger a report?

- Abnormal lab results
- AEs occurring from drug withdrawal or drug interactions
- Drug abuse or misuse, with or without event
- Overdose, intentionally or accidentally, with or without event
- Error in drug treatment process (medication error), with or without event
- Off-label use, with or without event
- Lack of efficacy
- Occupational exposure
- Drug exposure during pregnancy and lactation, with or without AE
- Adverse events occurring in breastfeeding infants
- Transmission of infectious agents
- Unexpected benefit



## **MEDICINES SIDE EFFECT REPORTING FORM (FOR CONSUMERS)**

औषधि दुष्प्रभाव सूचना फॉर्म (उपमोक्ताओं के लिए)
Indian Pharmacopoeia Commission, National Coordination Centre- Pharmacovigilance Programme of India, Ministry of Health & Family Welfare, Government of India.

भारतीय भेषज संहिता आयोग, राष्ट्रीय समन्वय केंद्र - भारतीय फार्माकोविजिलेंस कार्यक्रम, स्वास्थ्य एवं परिवार कल्याण मंत्रालय, भारत सरकार।

| 1.Patient Details/ रोगी का वि   | AMORE III                                    |                   |                          |                                     |  |  |  |  |  |  |  |  |
|---|--|-------------------|--------------------------|-------------------------------------|--|--|--|--|--|--|--|--|
| Patient Initials/<br>रोगी के आद्याक्षर:   | Gender/ लिंग (v): Male/ पुरूष Female/ स्त्री |                   |                          |                                     |  |  |  |  |  |  |  |  |
| रोगी के आद्याक्षर: Other/ अन्य  |  |                   |                          |                                     |  |  |  |  |  |  |  |  |
| a. Reason(s) for taking medicine(s)(Disease/Symptoms)/ दवा(दवाएं) लेने का कारण (रोग/लक्षण):   |  |                   |                          |                                     |  |  |  |  |  |  |  |  |
| a. neason(s) for taking inequality observes symptoms // add add and all all all all all all all all all al  |  |                   |                          |                                     |  |  |  |  |  |  |  |  |
| b. Medicines Advised by/ दवाई की सलाह देने वाला (v): Doctor/ डॉक्टर 🔲 Pharmacist/ फॉर्मासिस्ट 🔲 Friends/Relatives/ <u>मित्र</u> / रिश्तेदार 🔲         |  |                   |                          |                                     |  |  |  |  |  |  |  |  |
| Self (Past disease experienced/No past disease experienced)/ स्वयं (पूर्व बीमारी का अनुभव/पूर्व बीमारी का कोई अनुभव नहीं)                             |  |                   |                          |                                     |  |  |  |  |  |  |  |  |
| 3. Details of Person Reporting the Side Effect/ दुष्प्रमाव की सूचना देने वाले व्यक्ति का विवरण  |  |                   |                          |                                     |  |  |  |  |  |  |  |  |
| Name (Optional)/ नाम (वैकल्पिक):  |  |                   |                          |                                     |  |  |  |  |  |  |  |  |
| Address/ पता:   |  |                   |                          |                                     |  |  |  |  |  |  |  |  |
|   |  |                   |                          |                                     |  |  |  |  |  |  |  |  |
| Telephone No/ टेलीफोन नं:   |  | Email/ ईमेल:      |                          |                                     |  |  |  |  |  |  |  |  |
|   | g/Taken/ ली जा रही है / ली जा चुकी दवाई :    |                   |                          |                                     |  |  |  |  |  |  |  |  |
| Name of Medicines/  | Quantity of Medicines taken (e.g. 250 mg,    | Expiry Date of    | Date of Start of         | Date of Stop of                     |  |  |  |  |  |  |  |  |
| दवाइयों के नाम  | Two times a day )/ ली गई दवाई की मात्रा      | Medicines/ दवा के | Medicines/               | Medicines/ दवाइयां<br>रोकने की तिथि |  |  |  |  |  |  |  |  |
|   | (उदाहरण के लिए 250 मिग्रा, एक दिन में दो     | निष्क्रिय होने की | दवाइयां आरंभ             |                                     |  |  |  |  |  |  |  |  |
|   | बार)   | तिथि              | करने की तिथि             |                                     |  |  |  |  |  |  |  |  |
|   |  |                   | dd/mm/yy                 |                                     |  |  |  |  |  |  |  |  |
|   |  |                   | dd/mm/yy                 | dd/mm/yy                            |  |  |  |  |  |  |  |  |
|   |  |                   | dd/mm/yy                 | dd/mm/yy                            |  |  |  |  |  |  |  |  |
| Dosage form/खुराक का स्वरूप(v) : Tablet/ गोली (टेबलेट) 🔲 Capsule/ कैप्सूल 📗 Injection/ इंजेक्शन 🔲 Oral Liquids/ मौखिक                                 |  |                   |                          |                                     |  |  |  |  |  |  |  |  |
| तरल If Others (Please Specify)/यदि अन्य (कृपया निर्दिष्ट करें)  |  |                   |                          |                                     |  |  |  |  |  |  |  |  |
| 5. About the Side Effect/ दुः   | ध्रभाव के बारे में                           |                   |                          |                                     |  |  |  |  |  |  |  |  |
| When did the side effect sta  | rt?/ दुष्प्रभाव की शुरूआत कब हुई थी? 📁 🗔     | d/mm/yy Sid       | e Effect is still Contin | uing ( Yes/No)/                     |  |  |  |  |  |  |  |  |
| When did the side effect sto  | p?/ दुष्प्रमाव कब समाप्त हुआ था?             | dd/mm/vv ar       | या दुष्प्रमाव जारी है (ह | <b>ं √ नहीं)•</b> dd/mm/w           |  |  |  |  |  |  |  |  |
| When did the side effect sto  | 517 3 34 114 474 (1-114) GOL AL:             | oo, many yy       | 11 231114 011/1 0 10     | 17 -101). Carrining yy              |  |  |  |  |  |  |  |  |
| 6.How bad was the Side Effect? (Please √ the boxes that Apply)/ दुष्प्रमाव कितने हानिकाकर थे? (कृपया जो लागू हो, उस पर √ का निशान लगाएं)              |  |                   |                          |                                     |  |  |  |  |  |  |  |  |
| Did not affect daily activities/ दैनिक गतिविधियां प्रमावित नहीं हुई थी Affect daily activities/ दैनिक गतिविधियां प्रमावित हुई                         |  |                   |                          |                                     |  |  |  |  |  |  |  |  |
| Admitted to hospital/ अस्पताल ले जाना पड़ा Death/ मृत्यु  |  |                   |                          |                                     |  |  |  |  |  |  |  |  |
| Others/ अन्य  |  |                   |                          |                                     |  |  |  |  |  |  |  |  |
| 7.Describe the Side Effect (What did you do to manage the side effect?)/ दुष्प्रमाय की व्याख्या करें (आपने दुष्प्रमायों से छुटकारा प्रापा करने के लिए |  |                   |                          |                                     |  |  |  |  |  |  |  |  |
| क्या किया)?   |  |                   |                          |                                     |  |  |  |  |  |  |  |  |
|   |  |                   |                          |                                     |  |  |  |  |  |  |  |  |
|   |  |                   |                          |                                     |  |  |  |  |  |  |  |  |
|   |  |                   |                          |                                     |  |  |  |  |  |  |  |  |
|   |  |                   |                          |                                     |  |  |  |  |  |  |  |  |
|   |  |                   |                          |                                     |  |  |  |  |  |  |  |  |
|   |  |                   |                          |                                     |  |  |  |  |  |  |  |  |

This reporting is voluntary, has no legal implication and aims to improve patient safety. Your active participation is valuable. The information provided in this form will be forwarded to ADR Monitoring Centre for follow-up. You are requested to cooperate with the programme officials when they contact you for more details. Please do report even if you do not have all the information.

यह रिपोर्टिंग स्वैच्छिक है, कोई कानूनी निहितार्थ नहीं है और इसका लक्ष्य मरीज की सुखा में सुधार करना है। आपकी सक्रिय भागीदारी मूल्यवान है। इस फॉर्म में दी गई जानकारी की अनुवर्ती कार्रवाई हेतु एडीआर निगरानी केंद्र को भेजा जाएगा। आपसे अनुरोध है कि आप कार्यक्रम के अधिकारियों का सहयोग करें जब ये अधिक जानकारी प्राप्त करने के लिए आपसे संपर्क करें। कृपया पूर्ण जानकारी न होने पर भी सूचित करें।



#### SUSPECTED ADVERSE DRUG REACTION REPORTING FORM

For VOLUNTARY reporting of Adverse Drug Reaction by Healthcare Professionals

INDIAN PHARMACOPOEIA COMMISSION (National Coordination Centre-Pharmacovigilance Programme of India)


Ministry of Health & Family Welfare, Government of India Sector-23, Raj Nagar, Ghaziabad-201002

|   |               |        |                  |                      |            |                    |                            |                |                            | _   |   |              |          |                        |            |           |                       |             |  |
|---|---------------|--------|------------------|----------------------|------------|--------------------|----------------------------|----------------|----------------------------|---|---|--------------|----------|------------------------|------------|-----------|-----------------------|-------------|--|
| A. PATIENT INFORMATION                                    |               |        |                  |                      |            |                    |                            |                |                            |   | Reg. No. /IPD No. /OPD No. /CR No. :                              |              |          |                        |            |           |                       |             |  |
| 1. Pat  | ient Initials |        | Age at the time  |                      |            | 3. M 🗆 F 🗆 Other 🗆 |                            |                |                            | A   | AMC Report No. :  |              |          |                        |            |           |                       |             |  |
| Event or Date of E  |               |        | 4. WeightKgs     |                      |            |                    |                            | V              | Worldwide Unique No. :     |   |   |              |          |                        |            |           |                       |             |  |
| B. SU   | SPECTED AD    | VER    | SE REAC          | TION                 |            |                    |                            |                |                            | 1.  | 12. Relevant tests/ laboratory data with dates                    |              |          |                        |            |           |                       |             |  |
| 5. Event/Reaction start date (dd/mm/yyyy)                 |               |        |                  |                      |            |                    |                            |                |                            |   |   |              |          |                        |            |           |                       |             |  |
| 6. Event/Reaction stop date (dd/mm/yyyy)                  |               |        |                  |                      |            |                    |                            |                |                            |   |   |              |          |                        |            |           |                       |             |  |
| 6 (A). Onset Lag Time                                     |               |        |                  |                      |            |                    |                            |                |                            |   |   | W. D. O. P.  |          |                        |            |           |                       |             |  |
| 7. Describe Event/Reaction with treatment details, if any |               |        |                  |                      |            |                    |                            |                | pı                         | 13. Relevant medical/medication history (e.g. allergies, race, pregnancy, smoking, alcohol use, hepatic/renal dysfunction, past surgery etc.) |   |              |          |                        |            |           |                       |             |  |
|   |               |        |                  |                      |            |                    |                            |                | aı                         | 14. Seriousness of the reaction: No □ if Yes □(please tick anyone) □ Death (dd/mm/yyyy) □ Congenital-anomaly                                  |   |              |          |                        |            |           |                       |             |  |
|   |               |        |                  |                      |            |                    |                            |                |                            |   | Li  | fe thr       | eatening | 3                      |            | □ Dis     | ability               |             |  |
|   |               |        |                  |                      |            |                    |                            |                |                            | □Hospitalization/Prolonged □ Other Medically important  |   |              |          |                        |            |           |                       |             |  |
|   |               |        |                  |                      |            |                    |                            |                |                            | 1.  | 15. Outcomes  |              |          |                        |            |           |                       |             |  |
|   |               |        |                  |                      |            |                    |                            |                |                            |   | □ Recovered □ Recovering □ Not recovered                          |              |          |                        |            |           |                       |             |  |
|   |               |        | and the state of | -                    |            |                    |                            |                |                            |   | Fa  | atal         | [        | ] F                    | Recovered  | d with se | quelae                | □ Unknown   |  |
| C. SU   | SPECTED M     | EDIC   | ATION(S          | )                    |            | _                  |                            | 1 0            |                            |   |   |              |          |                        |            |           |                       | <b>41</b> 8 |  |
| SMOL  | 8. Name       |        | Manufacturer     |                      | Batch N    | lo. Exp. Da        |                            | Dose           | Route                      | Freque<br>(OD, E  | quency Therapy dates D. BD Date Indication Causality              |              |          |                        |            |           |                       |             |  |
| 3.140   | (Brand/Gene   | ric)   | (if kno          | wn)                  | / Lot N    | o. k               | nown                       | ) used         | used                       | etc.  |   | Date         | started  | ed Date Indication Ass |            |           |                       | Assessment  |  |
| j   |               |        |                  |                      |            |                    |                            |                |                            |   |   |              |          |                        | -16 %-     |           |                       |             |  |
| ii  |               |        |                  |                      |            | -                  |                            |                |                            |   |   |              | 3        |                        |            |           |                       | 24          |  |
| iii<br>iv*  |               |        | 45               | -                    |            |                    |                            | - <del>-</del> |                            |   | _   |              |          |                        |            |           |                       | A-P-        |  |
|   | . Action Take | n (ple | ease tick)       |                      |            |                    |                            |                |                            | 10. Re  | acti  | on re        | appeare  | d af                   | ter reintr | oduction  | ı (pleas              | e tick)     |  |
| as  | Drug _        |        | ncreased         | S200                 | ose        | Dos                | e not                      | Not            | Unknown                    |   | 822 5 8222 8  |              |          |                        |            |           |                       |             |  |
| 50  | vithdrawn Do  | se II  | icreaseu         | red                  | educed cha |                    | nanged applicab            |                | e                          | ı   | Yes   |              | No       |                        | cnect      | unknowi   | known Dose (if reintr |             |  |
| i   |               |        |                  | ē.                   | X          |                    |                            |                |                            |   |   |              |          |                        | _          |           |                       |             |  |
| iii   |               |        |                  | ý.                   | *          |                    | 9                          |                | 3                          |   |   |              | š.       |                        |            |           | 8                     |             |  |
| ìv  |               |        |                  |                      |            |                    |                            |                |                            |   |   |              |          |                        |            |           |                       |             |  |
| 11. Cc  | oncomitant m  |        |                  | t inclu              | ıding se   | lf-me              | dicati                     | on and he      |                            |   | the   | erapy        |          |                        |            | used to   | treat re              | action)     |  |
| S.No Name (Brand/Generic)                                 |               |        | Dose<br>used     | Dose Route used used |            |                    | Frequency (OI<br>BD, etc.) |                | Therapy<br>Date<br>started |   | y dates<br>Date<br>stopped  |              |          | Indication             |            |           |                       |             |  |
| ì   |               |        |                  |                      |            |                    |                            | 27             |                            |   | Ť   | J. C. C.     |          |                        | орран      |           |                       |             |  |
| ii  |               |        |                  |                      |            |                    | 2                          | 27             |                            |   |   |              | 0        |                        |            |           |                       |             |  |
| iii*  | ianal lufanu  |        | 7940             |                      |            |                    |                            | e e            |                            |   |   | January 1989 | app.     |                        |            | 9         |                       |             |  |
|   |               |        |                  |                      |            |                    |                            |                | T 1/2 / 1/2                |   | 77.00   | DETAIL       |          |                        |            |           |                       |             |  |
|   |               |        |                  |                      |            |                    |                            |                |                            | 16. Na  | .6. Name and Professional Address:                                |              |          |                        |            |           |                       |             |  |
|   |               |        |                  |                      |            |                    |                            |                | Pin:                       | Pin:E-mail  |   |              |          |                        |            |           |                       |             |  |
|   |               |        |                  |                      |            |                    |                            |                | Tel. No<br>Occup           | Tel. No. (with STD code)  Occupation:  Signature:   |   |              |          |                        |            |           |                       |             |  |
| -   |               |        |                  |                      |            |                    |                            |                | 50.00                      | 90.07 10.30 50 50 30 30 00 0000 1990 40 50 50 30 50   |   |              |          |                        |            |           |                       |             |  |
|   |               |        |                  |                      |            |                    |                            |                |                            |   | 17. Date of this report (dd/mm/yyyy):  Sig. and Name of Receiver- |              |          |                        |            |           |                       |             |  |
|   |               |        |                  |                      |            |                    |                            |                |                            |   | tacted to the fullect extent. Submission of a report does not     |              |          |                        |            |           |                       |             |  |

Confidentiality: The patient's identity is held in strict confidence and protected to the fullest extent. Submission of a report does not constitute an admission that medical personnel or manufacturer or the product caused or contributed to the reaction. Submission of an ADR report does not have any legal implication on the reporter.



# Be Vigilant... and Report ADR...!!



## Role of patients reporting in Pharmacovigilance

Patients can provide first hand information on the adverse reactions experienced by them after taking medicine. They helps in early detection of ADRs and provide crucial information that can help taking regulatory actions.

If you suspect/ experience any adverse drug reaction, report it through the following:-



ADR PVPI
MOBILE
APPLICATION
Available on: Google Play Store





Let's join hands with PvPI for patient safety



**Issued in Public Interest** 

National Coordination Centre - Pharmacovigilance Programme of India

A WHO Collaborating Centre for Pharmacovigilance in Public Health Programmes and Regulatory Services Indian Pharmacopoeia Commission, Ministry of Health & Family Welfare, Government of India

Sector-23, Raj Nagar, Ghaziabad-201002 Email: pvpi.ipc@gov.in Website: www.ipc.gov.in





#### Indian Pharmacopoeia Commission

National Coordination Centre
Pharmacovigilance Programme of India
Ministry of Health & Family Welfare, Govt. of India
Sector-23, Raj Nagar, Ghaziabad-201002
Tel.: 0120-2783400, Extn.-155

# For any relevant Information/Suggestions/Query

Please Contact: Officer-in-Charge, Pharmacovigilance Programme of India

Email: pvpi.ipc@gov.in, lab.ipc@gov.in website: www.ipc.gov.in